V.P. Stus

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini, Elizabeth R. Plimack, V.P. Stus et al. · New England Journal of Medicine · 2019 · 3.3K citations · Full text

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack, Denis Soulières et al. · The Lancet Oncology · 2020 · 721 citations

Urology, Oncology, Genitourinary Cancer +6

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

Thomas E. Hutson, Vladimir Lesovoy, V.P. Stus et al. · The Lancet Oncology · 2013 · 404 citations

First-line Therapy, Urology, Axitinib Versus Sorafenib +8

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

J. Motsch, Cláudia Murta de Oliveira, V.P. Stus et al. · Clinical Infectious Diseases · 2019 · 384 citations · Full text

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

Keith S. Kaye, Tanaya Bhowmick, Symeon Metallidis et al. · JAMA · 2018 · 298 citations · Full text